Navigation Links
Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
Date:9/26/2007

SAN DIEGO, Sept. 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has been selected to be one of the inaugural companies in the new NASDAQ(R) NeuroInsights(R) Neurotech Index.

The NASDAQ NeuroInsights Neurotech Index is an index designed to track the performance of selected neurotechnology companies which are listed on one of the three major U.S. stock exchanges. The NASDAQ NeuroInsights Neurotech Index includes companies engaged in researching, developing, manufacturing and marketing pharmaceuticals, biologics, medical devices and diagnostics for the brain and nervous system. In addition to meeting minimum market criteria, the 32 companies included in the index must be identified by NeuroInsights as significantly involved in the neurotechnology industry, which includes treatments and diagnostics for disorders like Alzheimer's, addiction, anxiety, depression, epilepsy, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, sensory disorders, sleep disorders, stroke, and traumatic brain injury.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. San Diego firm selected for Madison Wi-Fi project
4. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
5. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
6. NASDAQ will continue to list Merge
7. NASDAQ grants Merge more time for compliance
8. NASDAQ will continue to list Merge
9. No word on NASDAQ extension for Merge
10. NASDAQ puts Merge on notice again
11. Wisconsin ranks 30th in New Economy index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Oncolinx, a spin-out of the ... has truly taken their cancer research out of this world. On April 22, ... Canaveral to the International Space Station’s (ISS) U.S. National Laboratory, managed by the ...
(Date:4/27/2017)... ... 2017 , ... This month Quorum Review IRB ... research studies, accelerates study startup, and improves participant engagement. Developed by Kinetiq ... first and only IRB-integrated eConsent solution . , “Our mission at Quorum is ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... on capillary thermal mass flow technology provide exponentially more accurate mass flow data ... 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, ...
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Communication Award goes to Jayson Lusk, a consummate communicator who promotes agricultural science ... advocate for science, as he explains how innovation and growth in agriculture are ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):